Talaris Therapeutics (NASDAQ:TALS) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reissued their buy rating on shares of Talaris Therapeutics (NASDAQ:TALS – Get Rating) in a research note published on Monday morning, Benzinga reports. They currently have a $12.00 ta
Q4 2022 EPS Estimates for Talaris Therapeutics, Inc. Cut by HC Wainwright (NASDAQ:TALS)
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) – Stock analysts at HC Wainwright decreased their Q4 2022 earnings per share estimates for Talaris Therapeutics in a report released on Monday
Talaris Therapeutics (TALS) Gets a Buy From H.C. Wainwright
Talaris Therapeutics Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
Talaris Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 01/30/2023 795.52% HC Wainwright & Co. → $12 Reiterates → Buy 10/24/2022 795.52% HC Wainwright & Co. $18 →
HC Wainwright & Co. Reiterates Buy on Talaris Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Talaris Therapeutics (NASDAQ:TALS) with a Buy and maintains $12 price target.
Contrasting Talaris Therapeutics (NASDAQ:TALS) & Pluri (NASDAQ:PLUR)
Talaris Therapeutics (NASDAQ:TALS – Get Rating) and Pluri (NASDAQ:PLUR – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on t
Stocks That Hit 52-Week Lows On Tuesday
 Tuesday's session saw 325 companies set new 52-week lows. 52-Week Low Highlights: Apple (NASDAQ:AAPL) was the biggest company in terms of market cap to set a new 52-week low.InMed Pharmaceuticals
Talaris Therapeutics (NASDAQ:TALS) Shares Down 0.9%
Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) shares were down 0.9% during mid-day trading on Monday . The stock traded as low as $1.08 and last traded at $1.10. Approximately 2,842 shares ch
We Think Talaris Therapeutics (NASDAQ:TALS) Needs To Drive Business Growth Carefully
Loading...
No Stock Yet